Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 2/20 | 0.45 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.45 |
| ▸ | MAP3K14 | Q99558 | 11/20 | 0.42 |
| ▸ | TTBK1 | Q5TCY1 | 7/20 | 0.41 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11970624 | 0.92 | PAK4 (0.42) | PAK4PIKFYVEMAP3K14TTBK1TTBK2 | |
| SCHEMBL11970523 | 0.88 | MAP3K14 (0.46) | PAK4PIKFYVEMAP3K14TTBK1GRM5 | |
| SCHEMBL11970739 | 0.88 | MAP3K14 (0.46) | PAK4PIKFYVEMAP3K14TTBK1GRM5 | |
| SCHEMBL11970651 | 0.88 | MAP3K14 (0.46) | PAK4PIKFYVEMAP3K14TTBK1GRM5 | |
| SCHEMBL11970633 | 0.87 | PAK4 (0.44) | PAK4PIKFYVEMAP3K14TTBK1TTBK2 | |
| SCHEMBL11970705 | 0.85 | PAK4 (0.42) | PAK4PIKFYVEMAP3K14TTBK1GRM5 | |
| SCHEMBL11970956 | 0.85 | PAK4 (0.42) | PAK4PIKFYVEMAP3K14TTBK1GRM5 | |
| SCHEMBL12001736 | 0.85 | TTBK1 (0.38) | MAP3K14TTBK1TTBK2GRM5KDM4E | |
| SCHEMBL11970478 | 0.84 | MAP3K14 (0.49) | PAK4PIKFYVEMAP3K14PRKD1 | |
| SCHEMBL11970488 | 0.84 | MAP3K14 (0.48) | PAK4PIKFYVEMAP3K14TTBK1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038460-A1 | 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor | GENENTECH, INC. (US) | 2015-02-05 | — | — | US | claimed |
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | GENENTECH, INC. (US) | 2012-08-23 | — | — | US | claimed |
| US-20150038460-A1 | 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor | GENENTECH, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038460-A1 | 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor | GENENTECH, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038460-A1 | 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor | GENENTECH, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-8901313-B2 | 6,5-heterocyclic propargylic alcohol compounds and uses therefor | GENENTECH, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901313-B2 | 6,5-heterocyclic propargylic alcohol compounds and uses therefor | GENENTECH, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901313-B2 | 6,5-heterocyclic propargylic alcohol compounds and uses therefor | GENENTECH, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| WO-2012123522-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | GENENTECH, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | GENENTECH, INC. (US) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | NFKB1, NFRKB, NFKBIA | PAK4 1856/4885PIKFYVE 3647/4885MAP3K14 519/4885 |
| US-20150038460-A1 | 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor | NFKB1, NFRKB, NFKBIA | PAK4 1856/4885PIKFYVE 3647/4885MAP3K14 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.